Followers | 4 |
Posts | 117 |
Boards Moderated | 0 |
Alias Born | 02/26/2017 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, September 16, 2017 3:48:51 PM
Leo and Dr. B are intelligent individuals and were very aware that they created a data release expectation within the market, and would have to somehow communicate its abandonment. They most certainly discussed information dissemination strategy.
Dr. B's recent presentation provided a perfect venue to use a direct approach. In discussing the P trial (which he did), Dr. B could have addressed the issue with a succinct comment or two to the entire investor community, about their decision and reasons behind it and moved on. Then follow up with a blog post containing more information about investigator bias in clinical trials. Done. Over.
Instead they chose to employ classic damage control methodology (which all companies and CEO's do) in choosing not tackle the issue head on; rather to leak the information quietly via an email response knowing it would be posted to iHub, and following up with a throw-down PR as a diversionary measure.
The thought here is by addressing the issue in direct fashion now they would draw unnecessary attention to it and make it into a bigger deal than what it truly is. Now that they've "softened the blow", they'll come back at a later date with more explanation and proclaim "no big deal".
They used the same tactic back in the spring to announce the P trial delay, which IMO is a much bigger deal in terms of financial risk to the company than whether or not interim data is released. It didn't work too well then. I am not a big fan of the strategy, particularly as an automatic response to non-positive news.
Unfortunately, it seems as though they've added a lot of unnecessary stink to the situation which could have been diffused rather easily and in a much more credible manner.
I do suspect the CRO had concerns about an interim release. This is the benign and rational explanation.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM